ASRS 2023: Megan Baldwin, CEO of Opthea Limited shares updates on sozinibercept

Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Megan Baldwin, PhD:

Hello, I'm Megan Baldwin. I'm CEO and Managing Director of Opthea Limited. Opthea Limited is here at the ASRS, in Seattle. We will have a presentation by Dr Dante Pierramici on Monday of this week at ASRS. He'll be talking about OPT-302, which is also just announced to be called sozinibercept. Though, he'll be talking about the pharmacokinetic and safety data that we've demonstrated with the molecule to date. We are currently in phase 3 clinical development, recruiting patients globally for our product, which is in development in combination with both Eylea, or aflibercept, as well as Lucentis ranibizumab. And the objective of our approach is to provide additional clinical benefit visual acuity improved outcomes for patients on top of standard of care.

It will mean that ophthalmologist, physicians worldwide have an additional therapeutic option for patients in order to improve their clinical outcomes, which I think is the number one unmet medical need for patients right now. Right now, there's very limited treatment options. We understand that the VEGF-A inhibitors are a very clinically, you know, commercially successful class of drugs. But the fact is that many, many patients actually don't respond optimally, and that there's additional opportunity to provide visual acuity benefit across the board for many, many patients worldwide. And that's what we want to do with sozinibercept, OPT-302, which is a molecule that achieves a broader blockade of the validated pathways in the disease.